GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Total Receivables

Concord Biotech (BOM:543960) Total Receivables : ₹3,496 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Total Receivables?

Concord Biotech's Total Receivables for the quarter that ended in Mar. 2024 was ₹3,496 Mil.


Concord Biotech Total Receivables Historical Data

The historical data trend for Concord Biotech's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech Total Receivables Chart

Concord Biotech Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Total Receivables
1,929.94 2,132.58 2,590.63 3,121.14 3,496.09

Concord Biotech Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24
Total Receivables Get a 7-Day Free Trial 2,590.63 - 3,121.14 2,670.44 3,496.09

Concord Biotech Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Concord Biotech Total Receivables Related Terms

Thank you for viewing the detailed overview of Concord Biotech's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Concord Biotech (BOM:543960) Business Description

Traded in Other Exchanges
Address
Iscon Cross Road, S.G. Highway, 16th floor, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015
Concord Biotech Ltd is a Research & development-driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.

Concord Biotech (BOM:543960) Headlines

No Headlines